Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results

European Radiology

Volumn 26, Issue 8, 2016, Pages 2502-2509

  Park, Sung Yoon ^a   Oh, Young Taik ^a   Jung, Dae Chul ^a   Cho, Nam Hoon ^a   Choi, Young Deuk ^a   Rha, Koon Ho ^a   Hong, Sung Joon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biochemical recurrence; MRI; PI RADS; Prostate cancer; Radical prostatectomy

Indexed keywords

GADOTERATE MEGLUMINE; PROSTATE SPECIFIC ANTIGEN; SCOPOLAMINE BUTYL BROMIDE;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SIZE; FOLLOW UP; GENITAL SYSTEM DISEASE ASSESSMENT; GLEASON SCORE; HUMAN; IMAGE GUIDED BIOPSY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2; PROSTATECTOMY; SEMINAL VESICLE; TRANSRECTAL ULTRASONOGRAPHY; TUMOR INVASION; VERY ELDERLY; DIAGNOSTIC IMAGING; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84946779941     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-015-4077-5     Document Type: Article

References (35)

1. Stephenson AJ, Scardino PT, Eastham JA et al (2006) Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98:715–717
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–523
3. Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467–479
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597
5. Boorjian SA, Thompson RH, Tollefson MK et al (2011) Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 59:893–899
6. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J (2010) Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 170:1390–1395
7. Fuchsjager MH, Shukla-Dave A, Hricak H et al (2009) Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU Int 104:315–320
8. Zakian KL, Hricak H, Ishill N et al (2010) An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy. J Urol 184:2320–2327
9. Park SY, Kim CK, Park BK, Lee HM, Lee KS (2011) Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results. Eur Radiol 21:1111–1118
10. Park JJ, Kim CK, Park SY, Park BK, Lee HM, Cho SW (2014) Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy. AJR Am J Roentgenol 202:W459–W465
11. Westphalen AC, Koff WJ, Coakley FV et al (2011) Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume. Radiology 261:477–486
12. Riaz N, Afaq A, Akin O et al (2012) Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy. Int J Radiat Oncol Biol Phys 84:707–711
13. Kivrak AS, Paksoy Y, Erol C, Koplay M, Ozbek S, Kara F (2013) Comparison of apparent diffusion coefficient values among different MRI platforms: a multicenter phantom study. Diagn Interv Radiol 19:433–437
14. Sasaki M, Yamada K, Watanabe Y et al (2008) Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 249:624–630
15. Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757
16. Rosenkrantz AB, Kim S, Lim RP et al (2013) Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 269:482–492
17. Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM (2014) Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol. doi:10.1016/j.eururo.2014.10.033
18. Hoeks CM, Somford DM, van Oort IM et al (2014) Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study. Investig Radiol 49:165–172
19. Roethke MC, Kuru TH, Schultze S et al (2014) Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol 24:344–352
20. Renard-Penna R, Mozer P, Cornud F et al (2015) Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy. Radiology. doi:10.1148/radiol.14140184:140184
21. American Collage of Radiology. PI-RADS v2. http://www.acr.org/Quality-Safety/Resources/PIRADS. Assessed January 10, 2015
22. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
23. Vargas HA, Akin O, Franiel T et al (2011) Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 259:775–784
24. Vos EK, Litjens GJ, Kobus T et al (2013) Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol 64:448–455
25. Hattori S, Kosaka T, Mizuno R et al (2014) Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy. BJU Int 113:741–747
26. Kim JY, Kim SH, Kim YH, Lee HJ, Kim MJ, Choi MS (2014) Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection. Radiology 271:435–444
27. Arumainayagam N, Ahmed HU, Moore CM et al (2013) Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology 268:761–769
28. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P (2002) Prognostic value of the Gleason score in prostate cancer. BJU Int 89:538–542
29. Walz J, Chun FK, Klein EA et al (2009) Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol 55:412–419
30. Kayat Bittencourt L, Litjens G, Hulsbergen-van de Kaa CA, Turkbey B, Gasparetto EL, Barentsz JO (2015) Prostate Cancer: The European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for Predicting Extraprostatic Extension by Using 3-T Multiparametric MR Imaging. Radiology. doi:10.1148/radiol.15141412:141412
31. Freedland SJ, Humphreys EB, Mangold LA et al (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433–439
32. Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG (2012) Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 30:1857–1863
33. Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA (2014) Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65:20–25
34. von Bodman C, Godoy G, Chade DC et al (2010) Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol 184:143–148
35. Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55:1251–1265